Navigation Links
Gleevec for Lung Disease

Pulmonary fibrosis is a progressive lung disease that, according to the Pulmonary Fibrosis Foundation, claims the lives of 40,000 people every year. There's often not a known cause although// smoking and some occupations are risk factors. Now, a new treatment may give patients what they're looking for -- more time.

Michael Dixon is enjoying every minute he has with his wife Debbie. Earlier this year, his doctor told him he had a lung disease called pulmonary fibrosis. "He gave me, at most, a 50/50 chance of making five years, and that's when it sunk in," Michael tells Ivanhoe.

He only has half of his lung capacity right now, but as time passes, it will decrease even more. He says, "The hardest part was telling my kids that I might not be around."

Michael is determined to stay around, so he enrolled in a study at Tulane University Health Sciences Center with Pulmonologist Joseph Lasky, M.D..

"The idea of the use of Gleevec is to stop the disease from getting worse once the patient has been diagnosed," Dr. Lasky tells Ivanhoe.

Gleevec has received national attention for its success in treating leukemia. Because fibrosis and cancer share some of the mechanisms of the development of the disease, Dr. Lasky says doctors thought it might be of some benefit for the patients who have fibrosis.

In this disease, scars form on the lungs. Those scars soon take over, and the lungs stop working. Based on lab studies, Dr. Lasky says Gleevec should stop that scarring.

"At best, we hope to stop the progression of the disease," he says. "It's our hope that the treatment of Gleevec will increase the length of their life as well as improve the quality."

The research is currently ongoing to find out just how effective Gleevec is.

For the study, Michael takes six pills a day and hopes they'll give him and his lungs a little more time. "I'd say 99 percent of the time, I believe it's going to work out. I'm hopeful," he says.

There are several sites involved in the study across the United States and one site in Mexico. Most common side effects of Gleevec include nausea and fluid retention.


'"/>




Related medicine news :

1. Gleevec gets hopeful results
2. "Miracle" Cancer Drug Gleevec Can be Toxic to the Heart
3. Novartis Gleevec Found Effective in Treating Gastro-intestinal Tumors
4. Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
5. Vitamins-The answer to Heart Disease?
6. Link between Constipation and Parkinsons Disease
7. Levels Of Blood Proteins May Help Heart Disease Care
8. New Drug PP188 Helps Sickle Cell Disease
9. Gene Treatment for Heart Disease
10. Legume Consumption Can Cut Heart Disease Risk
11. Link Between Infection And Heart Disease
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: